Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL1524371 | 0.89 | GPR3 (0.40) | PTPN1 | |
| Hydrochloric Acid SCHEMBL17583811 | 0.79 | BCHE (0.30) | — | |
| Iodide SCHEMBL28722276 | 0.79 | BCHE (0.30) | — | |
| Bromide SCHEMBL28959814 | 0.79 | BCHE (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL4413284 | 0.79 | TDP1 (0.39) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL30570819 | 0.69 | GPR3 (0.46) | PTPN1 | |
| Biphenyl SCHEMBL1050411 | 0.67 | PTPN1 (0.58) | PTPN1 | |
| Hydrochloric Acid SCHEMBL19183368 | 0.67 | TSHR (0.43) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL789189 | 0.66 | ALDH1A1 (0.50) | PTPN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL30552135 | 0.66 | ALDH1A1 (0.50) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2873674-B1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10322173-B2 | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2019-06-18 | — | — | US | disclosed |
| US-10149905-B2 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-10144933-B2 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-04 | — | — | US | disclosed |
| US-9617547-B2 | Chiral nucleic acid adjuvant | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| EP-3095460-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3095459-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3095461-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING IMMUNITY INDUCTION ACTIVITY, AND IMMUNITY INDUCTION ACTIVATOR | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160331836-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160333349-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING IMMUNITY INDUCTION ACTIVITY, AND IMMUNITY INDUCTION ACTIVATOR | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160331835-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2873674-A1 | CHIRAL NUCLEIC ACID ADJUVANT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2015-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166999-A1 | CHIRAL NUCLEIC ACID ADJUVANT | IFNAR1, IFNG, IRF3 | PTPN1 111/4885 |
| US-20160331836-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTITUMOR EFFECT AND ANTITUMOR AGENT | DDX21, DDX24, TLR9 | PTPN1 600/4885 |
| US-10149905-B2 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent | DDX21, DDX24, TLR9 | PTPN1 600/4885 |
| US-10322173-B2 | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent | TLR9, POLL, MRGPRX2 | PTPN1 760/4885 |
| US-10144933-B2 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator | TLR9, IRF3, TLR3 | PTPN1 938/4885 |
| US-20160331835-A1 | CHIRAL NUCLEIC ACID ADJUVANT HAVING ANTI-ALLERGIC ACTIVITY, AND ANTI-ALLERGIC AGENT | TLR9, MRGPRX2, POLL | PTPN1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.